AstraZeneca's Nexium now has generic competition, toxicity worries researchers about new cancer approaches and a former Pfizer exec will now lead an e-cigarette company.
Two new classes of medicines have shown unparalleled efficacy in oncology, but there are growing concerns about the treatments' safety.
News flowing from Bristol-Myers Squibb and Merck show the two companies may fight for elbow room among lung cancer patients with drugs that have already started building credibility in other indications.
The FDA told Pfizer that it isn't bothering with a committee review for the experimental breast cancer drug Ibrance (palbociclib). The part two news exciting investors: Pfizer and the FDA are already talking labels.
The drugmaker has signed a deal with two biotechs with novel gene-sequencing capabilities.
NIH project for genome sequencing of newborns commences; remote care, next-gen. DNA sequencing top list of 2014 healthcare-market trends; WHO plans evaluation of contagious-disease response.
FDA's accelerated approval on the checkpoint inhibitor chips away at Merck's first-mover advantage in the US market.
BMS cancer drug Opdivo becomes the second PD-1 inhibitor to secure US approval ; Omnicare hit by more kickback charges; India looks to rein in pharma marketing.
Express Scripts taps AbbVie hep. C drug as exclusive option; AZ first-in-class cancer drug approved; Cubist gains OK for superbug fighter.
The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million
Shire may bid on NPS Pharmaceuticals; Amgen says cancer drug will cost $178,000; Takeda has a new head of R&D.
Studies by Australian company Novogen are said to demonstrate, for the first time, that a drug highly effective against brain cancers has the same high potency against melanoma.
The treatment reduces risk by half compared to widely used Zelboraf.
The regulator noted in its early 2014 retrospective that it set a high mark for the number of approved rare disease drugs this year, and that insufficient information is the reason many breakthrough status requests get bounced.
United Healthcare tests an all-in-one cancer payment model, Pfizer inks a worldwide commercialization license for a human growth factor hormone, and the Commonwealth Fund grades Medicare as the program nears its 50th.
The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.
Early trials of Venetoclax, formerly known as ABT-199, indicate the experimental drug execs consider an oncology cornerstone continues to show promise.
Transfer of rights to the experimental cancer drug hinges on completion of Novartis/GSK asset swap.
Jakafi becomes the first drug approved for treating polycythemia vera.
Ackman walks away with $2.5 billion, despite no Allergan deal; Ranbaxy sues FDA over generic Nexium rights; Indian government's Health Ministry recommends breaking BMS cancer drug patent.
The Pennsylvania company says it will continue to develop its IO treatment, even without Roche's support.
Actavis and Allergan have a $66-billion-dollar deal, Merck's Vytorin hits its endpoint, and Pfizer puts up $850 million for an experimental cancer drug.
A 4-1BB agonist highlights a discussion with analysts on the drug giant's immunoncology pipeline, with a number of combination options to be tested next year.
Researchers find that jet lag has an impact on the microscopic level.
The Hill outlines its healthcare expectations with a GOP Congress, Sanofi's executive shakeup may have an impact on MannKind's Afrezza launch, AstraZeneca's olaparib may have prostate cancer prospects, the FDA granted orphan status to an experimental Merrimack pancreatic cancer drug, and researchers are struggling to get Ebola virus samples.
The FDA will vote for or against the breast cancer drug by April 13, 2015.
The drugmaker is poised to cut 14 pipeline projects loose.
Inversion rules have Medtronic asking for a Covidien do-over, Roche's Perjeta has "unprecedented success," while AstraZeneca's Iressa does not.
Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.
Keytruda was the first of the new PD-1 class of immuno-oncology drugs to reach the US, but Bristol-Myers Squibb and Ono could run away with the competition, according to one analyst.
This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.
- Novartis psoriasis drug approval could upend market
- Sandoz gets ready to make the biosimilar case with oncologists
- Guidemark Health jumpstarts rebrand, brings on big-agency grad
- MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics
- Nurse practitioner workforce has just about doubled